Loading provider…
Loading provider…
Pulmonary Disease Physician in New Bedford, MA
NPI: 1124080312Primary Practice Location
ST LUKES HOSPITAL
101 Hospital Dr, Columbus, NC
Primary Employer
Pulmonary and Sleep Medicine Associates Inc
southcoast.org
HQ Phone
Get MD Curtis's Phone Numberphone_androidMobile
Get MD Curtis's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardRI State Medical License
MA State Medical License
RI State Medical License
1990 - 2026
MA State Medical License
1994 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Pulmonary Disease

American Board of Internal Medicine
Sleep Medicine
University of Massachusetts
MBA • 2014 - 2016
2014 - 2016
UMass Chan Medical School
umassmed.edu
Fellowship • Pulmonary Disease and Critical Care Medicine
1992 - 1995
Medical School
Until 1989
Rhode Island Hospital/Brown University Health
Residency • Internal Medicine
1989 - 1992
Boston University School of Public Health
MPH • 1982 - 1984
1982 - 1984
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 691 | 1,088 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 239 | 403 |
| 3 | 94060Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | 198 | 201 |
| 4 | 94729Measurement of lung diffusing capacity | 189 | 189 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 167 | 167 |
Metastatic papillary thyroid carcinoma to lung diagnosed by bronchoalveolar lavage.
Authors: Neil Aronin
Publication Date: 1996-01
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
Authors: Merkle, Florian T, Ghosh, Sulagna, Kamitaki, Nolan, Mitchell, Jana, Avior, Yishai, Mello, Curtis, Kashin, Seva, Mekhoubad, Shila, Ilic, Dusko, Charlton, Maura, Saphier, Genevieve, Handsaker, Robert E, Genovese, Giulio, Bar, Shiran, Benvenisty, Nissim, McCarroll, Steven A, Eggan, Kevin
Journal: Nature
Publication Date: 2017-04-26
Lead Sponsor: Orinove, Inc.
Collaborators: Vanderbilt University
Intervention / Treatment: DRUG: Placebo, DRUG: ORIN1001
Lead Sponsor: GlaxoSmithKline
Collaborators: Iqvia Pty Ltd
Intervention / Treatment: BIOLOGICAL: Placebo, DRUG: Standard of care (SoC), DEVICE: Pre-filled Syringes (PFS), BIOLOGICAL: GSK3511294 (Depemokimab), BIOLOGICAL: Mepolizumab, BIOLOGICAL: Benralizumab
Lead Sponsor: Lung Biotechnology PBC
Intervention / Treatment: DRUG: Placebo, DRUG: Beraprost Sodium 314d Modified Release Tablets